- Home
- HCI vs DAWN Comparison
HCI vs DAWN Comparison
Compare HCI & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | DAWN |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | 552 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HCI | DAWN |
|---|---|---|
| Price | $155.58 | $21.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $230.00 | $26.00 |
| AVG Volume (30 Days) | 99.6K | ★ 6.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $11.44 | $53.52 |
| Revenue Next Year | $7.67 | $27.10 |
| P/E Ratio | $9.97 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $129.58 | $5.64 |
| 52 Week High | $210.50 | $21.42 |
Technical Indicators
Market Signals| Indicator | HCI | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 81.51 |
| Support Level | $151.72 | $6.45 |
| Resistance Level | $158.85 | $21.40 |
| Average True Range (ATR) | 4.94 | 0.12 |
| MACD | -1.33 | 0.08 |
| Stochastic Oscillator | 23.02 | 99.50 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.